More good news in research: Clinical trials show dramatic results for Farxiga® in treating CKD
For individuals living with chronic kidney disease (CKD), advances in treatment offer significant hope for improved outcomes in slowing the disease’s progression and treating its comorbidities, especially cardiovascular disease.
In the news today are the results from the ground-breaking Phase III DAPA-CKD clinical trial showing that AstraZeneca’s Farxiga® (dapagliflozin) dramatically reduces risk for both progression of kidney disease and cardiovascular death in patients with and without diabetes.
Farxiga was approved by the FDA in May 2020 for patients with heart failure. AstraZeneca will ask the FDA to approve its use in treating CKD.
In a press release, the company’s head of research and development said, “With today’s results, Farxiga becomes the first SGLT2 inhibitor proven to significantly prolong the survival of patients with chronic kidney disease with and without type-2 diabetes and we look forward to sharing these data with regulatory authorities around the world. Farxiga is also the first medicine in its class to demonstrate benefit in treating both heart failure and chronic kidney disease in patients with and without type-2 diabetes, and reduce the risk of hospitalisation for heart failure and nephropathy in type-2 diabetes.”
SGLT2 inhibitors help type-2 diabetics by prompting the kidneys to eliminate excess blood glucose through the urine. Farxiga was shown in the study to cut the risk of dying from any cause for people suffering from chronic kidney disease by 31% when compared to a group on placebo.